Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

• Κύριοι συγγραφείς: Xinyu Yan (Συγγραφέας), Shouyue Zhang (Συγγραφέας), Yun Deng (Συγγραφέας), Peiqi Wang (Συγγραφέας), Qianqian Hou (Συγγραφέας), Heng Xu (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Frontiers Media S.A., 2018-09-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Checkpoint inhibitor (CPI) based immunotherapy (i.e., anit-CTLA-4/PD-1/PD-L1 antibodies) can effectively prolong overall survival of patients across several cancer types at the advanced stage. However, only part of patients experience objective responses from such treatments, illustrating large indi...